Charles River Laboratory has collaborated with Driv Bio to expand biology

On January 14, 2020, Charles River Laboratories (NYSE: CRL) announced that it has entered into a strategic partnership with JADE Biomedical, an end-to-end quality management service provider for the biopharmaceutical industry.
partnership reaffirms the company's commitment as a global development partner by expanding Charles River's biopharmaceutical testing capabilities and helping to meet its needs for biopharmaceutical products, particularly cell and gene therapy.
This strategic relationship will also accelerate the expansion of CGMP's international CGMP standard bio-molecular product testing business in Shanghai to a second laboratory in China, and further expand the complete biopharmaceutical quality technology contracting and testing business.
with the rapid development of the global biopharmaceutical industry, the demand for reliable professional contract service providers is also growing.
development of the global cell and gene therapy market requires scientific and professional quality management knowledge to navigate the complex regulatory environment around the world.
's deep understanding of global trends and local environment, as well as its business model designed to support customers of all sizes around the world, from local start-ups to global companies, is an important part of Charles River's global bio-products service chain, and the second testing laboratory, which will be launched this summer, will further enhance its CGMP and GLP testing capabilities and scale based on the growing needs of its customers.
we need a partner with global influence on the causes of our cooperation and developments in cell therapy.
And Charles River will rely on its industry-leading service strategy and regulatory expertise to help us better serve and support a growing number of businesses locally and globally." - Dr. Claudia Lin, founder and CEO of Drive Jade Bio, about Charles River Charles River providing pharmaceutical and biotechnology companies around the world with the necessary products and services to accelerate their drug research and development efforts.
dedicated employees are committed to serving our customers' needs, thereby facilitating and improving the discovery, early development and safe production of new therapies, and ultimately serving patients.
To learn about our unique product portfolio and extensive services, please visit River Investor Contact: Todd Spencer 781-222-6455 Vice President of Investor Relations todd.spencer@crl.com Charles River Media Contact: Amy Cianciaruso 781-222-6168 Vice President of Public Relations amy.cianciaruso@crl.com
As the world's first registered biopharmaceutical contract quality organization Bio-CQO®, the service modules of Jade Bio include quality assurance, product quality management, drug registration declaration, QC method verification and testing, CMC and analytical method development guidance, plant facility design and verification, cold chain management, etc.
founders and leadership teams are industry leaders with extensive experience working with NMPA, FDA, EMA, PMDA and PICS in the development and production quality management of polymer drugs.
we rely on a growing team of professionals to support our customers' industrialization from pre-IND to post-market by providing them with flexible and reliable customized quality and CMC systems and leading implementations.
testing services for driving jade organisms can provide compatible laboratory analysis and testing services for the world's advanced CGMP standards, supporting international product reporting needs.
our expertise covers a wide range of product types including monoclonal antibodies, antibody Eugenes, cells and gene therapy.
to learn more about Driving Jade Bio and current recruitment positions, please visit The Driving Jade Bio Investment Contact: Claudia Lin Lin Qiao CEOclaudialin@jadebiomedical.com Driving Jade Biomedia Contact: James Vang Director of Marketing jamesvang@jadebiomedical.com